PDCD1 and pancreatic adenocarcinoma: Similarly, the combination of BH with anti-CTLA-4 and anti-PD-1 (anti–programmed cell death 1) antibodies results in maximal tumor control, survival, and favorable profiles of intratumoral lymphocytic infiltration in a murine model of pancreatic adenocarcinoma (88).